Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

ARTICLES

Cytopathology in focus: Small samples, big impact: cytology specimens in the molecular era

August 2025—Strides in medical imaging techniques and procurement methods have led to the acquisition of small diagnostic samples obtained by minimally invasive techniques. Over the same period, the breadth of molecular information that can be derived from limited tumor material has increased exponentially. In the age of targeted cancer therapy, the clinical utility of this information is substantial and, when coupled with the decreasing costs of molecular analysis, the information transformed the treatment landscape of cancer. These advances have brought cytology back into the spotlight as a potential source of material for biomarker analysis.

Cytopathology in focus: What’s new in ’25 head and neck SCC guideline?

August 2025—Human papillomavirus testing has become the standard of care in head and neck squamous cell carcinoma (HNSCC) because of the unique clinical features, staging, and treatment options for HPV-associated HNSCC. HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) exhibits a favorable prognosis and improved response to chemoradiation compared with conventional HNSCC and non-HPV-associated forms, and reporting the HPV status is frequently part of clinical trial enrollments. Many patients with OPSCC present with enlarged level II or III cervical lymph nodes and, as a result, cervical lymph node fine-needle aspiration is often the first, and sometimes only, tissue obtained for diagnostic testing. With a growing menu of options available to test for HPV status, including polymerase chain reaction, DNA in situ hybridization, mRNA ISH, liquid-based HPV assays, and p16 immunohistochemistry, it is not always clear when and which HPV test to use, especially when the diagnosis is made on a cytology specimen.

External controls critical to crucial assays

August 2025—CAP TODAY publisher Bob McGonnagle spoke on May 14 with Jessica Van Allen, PhD, technical support lead for ZeptoMetrix, and Meghan Starolis, MS, PhD, HCLD(ABB), senior science director for infectious diseases at Quest Diagnostics, Chantilly, Va.

Jessica VanAllen
Dr. Van Allen
Dr. Starolis
Dr. Starolis

Read the article:

Bob McGonnagle: Jessica Van Allen, I’d like to talk about some of the hot topics in molecular infectious disease testing, and you mentioned in our discussions offline that viral load testing for transplant viruses is becoming ever more important in the field. Can you make a few remarks about that?

Jessica Van Allen, PhD (Zepto­Metrix): There’s testing that is done using laboratory-developed tests and testing performed using FDA-cleared assays. Those are the two big buckets of testing in the labs of our customers. Meghan and I attended a conference recently at which a couple of the speakers talked about viral load testing for common transplant viruses—EBV, CMV, VZV, some adenoviruses. We’ve been playing in that field for a long time in terms of molecular controls for viruses, so they’re products we’ve had on the shelf. Continue reading …

Watch the full conversation:

This roundtable discussion is sponsored by ZeptoMetrix.

Familiar but newer: ICI-associated colitis

July 2025—For all the words that have been devoted to the topic of how to meditate, the path to enlightenment can be disarmingly simple: start by noticing. Likewise, there is a fairly simple set of instructions for untangling one of the vexing problems associated with immune checkpoint inhibitors. Though the drugs can create impressive antitumor response, they can also lead to immune-related adverse events (known as irAEs), including colitis and gastritis, which manifest as histologic changes that can be seen in both the upper and lower gastrointestinal tract. Left unaddressed, severe reactions can disrupt treatment. It’s complicated. And it’s not. The first step, says Raul S. Gonzalez, MD, professor of pathology and laboratory medicine and director of the gastrointestinal pathology service, Emory University School of Medicine, is cultivating a certain mindfulness. “We need to have knowledge that checkpoint inhibitors can cause immune-related adverse events such as gastritis and colitis, to be aware that these things happen,” says Dr. Gonzalez.

Too few phlebotomists—is Aletta the answer?

July 2025—It was one of those infamous winter days in Chicago. The phlebotomy staff were calling off work, and Gregory S. Retzinger, MD, PhD, had reached his breaking point. Phlebotomists tend to be in short supply, and Northwestern Memorial Hospital, where Dr. Retzinger is medical director of pathology clinical services, is no exception.

Pathology student interest groups—what makes them work

July 2025—Seventy-eight percent of those responding to a survey said their institutions have a pathology student interest group, and they said the most effective ways to engage and retain students are hosting regular events; providing mentorship, leadership, and shadowing opportunities; and offering participation incentives. Using social media and online platforms was reported to be less effective. “A surprise in the findings was the student respondents’ desire to have more faculty engagement. So while students may want to start an interest group and are engaged, they have a hard time getting these off the ground if they don’t have faculty support,” says coauthor Kalisha Hill, MD, MBA. “We’re finding that when the faculty are engaged with these student interest groups, they are much more successful.”

How high school students are learning about labs

July 2025—Two years into its program to introduce high school students to laboratory careers, Mayo Clinic in Rochester, Minn., is seeing the hoped-for interest and demand. Discover Mayo Clinic Lab Explorers Program is the name, and the program is open to students in grades nine through 12. “Over the last two years, we’ve had roughly 100 students participate, and both times we opened registration it was full within three to five days,” says Liana Michelfelder, talent solutions specialist with the Mayo Clinic human resources workforce development team. In the program’s second year, which took place this year in April, she says, there was a 60-student waiting list. “So we are seeing strong results so far,” Michelfelder says.